Silence Therapeutics
SLN
64 hedge funds and large institutions have $588M invested in Silence Therapeutics in 2024 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 17 increasing their positions, 11 reducing their positions, and 2 closing their positions.
1,500% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 2
88% more funds holding
Funds holding: 34 → 64 (+30)
70% more capital invested
Capital invested by funds: $345M → $588M (+$243M)
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
0.76% more ownership
Funds ownership: 19.11% → 19.87% (+0.76%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$44.1M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$25.9M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$23.4M |
| 4 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$20.7M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$32.4M |
| 2 |
LOAME
Lombard Odier Asset Management (Europe)
London,
United Kingdom
|
-$29.9M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$26.2M |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$10.2M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.69M |
SLN Hedge Fund Activity: Q1 2024 in Review
64 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q1 2024, worth a combined $588M — up 70% from $345M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new SLN positions and 2 closed out — a net gain of 30 holders — while 17 added to existing stakes and 11 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $44.1M. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $32.4M.
- 64 institutional investors held Silence Therapeutics (SLN) as of Q1 2024, up from 34 in Q4 2023.
- Funds reported $588M of Silence Therapeutics stock for Q1 2024, up 70% quarter-over-quarter.
- 32 funds opened new Silence Therapeutics positions in Q1 2024 and 2 closed out, a net change of +30 holders.
- The largest Silence Therapeutics buyer in Q1 2024 was Redmile Group, an estimated $44.1M added.
- The largest Silence Therapeutics seller in Q1 2024 was Lombard Odier Asset Management (USA), an estimated $32.4M sold.
Based on aggregated 13F filings for Q1 2024.